Literature DB >> 12210629

Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes.

François Curtin1, Douglas G Altman, Diana Elbourne.   

Abstract

Among clinical trials assessing a given treatment, often parallel and cross-over designs are used together. In the first paper of a series of three, we explore two methods to pool continuous outcomes in a meta-analysis combining parallel and cross-over trial designs: the weighted mean difference (WMD) and the standardized weighted mean difference (SWMD). The combined design meta-analytic formulae are based on a weighted average of the two design treatment estimates. A random effects model can be implemented. Both WMD and SWMD can be used, the choice of the method is determined by the type of outcomes obtained in the trials. Compared to the number of included subjects, the relative weight of the cross-over design is large in combined-design meta-analysis. Differences in the weight estimation between WMD and SWMD can also accentuate the relative weight of cross-over trials, which must be considered a case of design-specific bias. Copyright 2002 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2002        PMID: 12210629     DOI: 10.1002/sim.1205

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  56 in total

1.  Oscillating devices for airway clearance in people with cystic fibrosis.

Authors:  Lisa Morrison; Stephanie Milroy
Journal:  Cochrane Database Syst Rev       Date:  2020-04-30

Review 2.  Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment.

Authors:  Siavash Piran; Dominick Amato
Journal:  J Inherit Metab Dis       Date:  2010-03-25       Impact factor: 4.982

Review 3.  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma.

Authors:  J P Guevara; F M Ducharme; R Keren; S Nihtianova; J Zorc
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 4.  Amantadine for fatigue in multiple sclerosis.

Authors:  E Pucci; P Branãs; R D'Amico; G Giuliani; A Solari; C Taus
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 5.  Pharmacological interventions for clozapine-induced hypersalivation.

Authors:  Rebecca Syed; Katie Au; Caroline Cahill; Lorna Duggan; Yanling He; Victor Udu; Jun Xia
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

Review 6.  The acute effects of exercise on cigarette cravings, withdrawal symptoms, affect, and smoking behaviour: systematic review update and meta-analysis.

Authors:  Vaughan Roberts; Ralph Maddison; Caroline Simpson; Chris Bullen; Harry Prapavessis
Journal:  Psychopharmacology (Berl)       Date:  2012-05-15       Impact factor: 4.530

7.  Assay sensitivity and study features in neuropathic pain trials: an ACTTION meta-analysis.

Authors:  Robert H Dworkin; Dennis C Turk; Sarah Peirce-Sandner; Hua He; Michael P McDermott; John T Farrar; Nathaniel P Katz; Allison H Lin; Bob A Rappaport; Michael C Rowbotham
Journal:  Neurology       Date:  2013-05-22       Impact factor: 9.910

8.  The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents.

Authors:  Guilherme Polanczyk; Stephen V Faraone; Claiton H D Bau; Marcelo M Victor; Katja Becker; Reta Pelz; Jan K Buitelaar; Barbara Franke; Sandra Kooij; Emma van der Meulen; Keun-Ah Cheon; Eric Mick; Diane Purper-Ouakil; Philip Gorwood; Mark A Stein; Edwin H Cook; Luis Augusto Rohde
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-12-05       Impact factor: 3.568

Review 9.  Management of sexual dysfunction due to antipsychotic drug therapy.

Authors:  Hannah M Schmidt; Mathias Hagen; Levente Kriston; Karla Soares-Weiser; Nicola Maayan; Michael M Berner
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

Review 10.  Macrolide antibiotics for cystic fibrosis.

Authors:  Kevin W Southern; Pierre M Barker; Arturo Solis-Moya; Latifa Patel
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.